IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

Gut

Volumn 65, Issue 9, 2016, Pages 1447-1455

  Vuitton, L ^a,b   Marteau, P ^c   Sandborn, W J ^d   Levesque, B G ^d   Feagan, B ^e   Vermeire, S ^f   Danese, S ^g   D'Haens, G ^h   Lowenberg, M ^h   Khanna, R ^e   Fiorino, G ^g   Travis, S ⁱ   Mary, J Y ^j   Peyrin Biroulet, L ^b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b CHU NANCY BRABOIS   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^j SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSENSUS DEVELOPMENT; CROHN DISEASE; CROHN DISEASE ENDOSCOPIC INDEX OF SEVERITY; DELPHI STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENDOSCOPY; HUMAN; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SIMPLE ENDOSCOPIC SCORE FOR CROHN DISEASE; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; GASTROINTESTINAL ENDOSCOPY; INTESTINE MUCOSA; METHODOLOGY; PATIENT ACUITY; PHYSIOLOGIC MONITORING; PROCEDURES; SEVERITY OF ILLNESS INDEX; STANDARDS;

CLINICAL TRIALS AS TOPIC; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL MUCOSA; MONITORING, PHYSIOLOGIC; PATIENT ACUITY; REMISSION INDUCTION; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 84941730242     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309903     Document Type: Article

References (53)

1. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83.
2. Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35.
3. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
4. No authors listed]. Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci 1987;32:1370-9.
5. Khanna R, Zou G, D'Haens G, et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 2016;65:1119-25.
6. Daperno M, Comberlato M, Bossa F, et al. Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2014;46:969-73.
7. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
8. Sipponen T, Nuutinen H, Turunen U, et al. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010;16:2131-6.
9. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-18.
10. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647-53.
11. Mary JY, Lémann M, Colombel JF, et al. GETAID. Endoscopic remission and response in Crohn's disease: an objective definition using CDEIS. Gut 2005;543 (Suppl):VIIpA50.
12. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
13. Olaison G, Sjödahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990;31:325-8.
14. Sandborn WJ, Van OEC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995;109:1808-17.
15. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999;50:667-71.
16. D'haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
17. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42.
18. D'Haens G, Baert F, van Assche G, et al., Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
19. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009;15:375-82.
20. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
21. Van der Woude CJ, Stokkers P, van Bodegraven AA, et al., Initiative on Crohn's and Colitis, The Netherlands. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm Bowel Dis 2010;16:1708-16.
22. Af Björkesten C-G, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2012;47:528-37.
23. Sandborn WJ, Gasink C, Gao L-L, et al., CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-28.
24. Rutgeerts P, Van Assche G, Sandborn WJ, et al., Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11.
25. Ferrante M, Colombel J-F, Sandborn WJ, et al., International Organization for the Study of Inflammatory Bowel Diseases. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013;145:978-86.
26. Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8.
27. Sands BE, Katz S, Wolf DC, et al. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013;62:1288-94.
28. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72.
29. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63.
30. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994;8:35-43.
31. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995;109:404-13.
32. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995;108:345-9.
33. Florent C, Cortot A, Quandale P, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 1996;8:229-33.
34. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127:723-9.
35. Herfarth H, Tjaden C, Lukas M, et al., Z T-1 Study Group. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 2006;55:1525-6.
36. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008;135:1123-9.
37. Nos P, Hinojosa J, Aguilera V, et al. Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease. Gastroenterol Hepatol 2000;23:374-8.
38. Ewe K, Böttger T, Buhr HJ, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999;11:277-82.
39. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology 1999;116:294-300.
40. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
41. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-61.
42. Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003;17:517-23.
43. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-6.
44. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-50.
45. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013;108:1731-42.
46. Prinsen CAC, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a "core outcome set". Trials 2014;15:247.
47. Peyrin-Biroulet L, Reinisch W, Colombel J-F, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95.
48. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24.
49. Feagan BG, Rutgeerts P, Sands BE, et al., GEMINI 1 Study Group. 0Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
50. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet Lond Engl 2015;385:1406-17.
51. Papamichael K, Archavlis E, Lariou C, et al. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, 2-year, single center, pilot study. J Crohns Colitis 2012;6:924-31.
52. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009;15:1460-6.
53. Reinisch W, Angelberger S, Petritsch W, et al., International AZT-2 Study Group. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010;59:752-9.